New hypertension drug VB19055 enters first human safety trial
NCT ID NCT07254481
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This early-stage study tests a new tablet called VB19055 in 86 healthy Chinese adults to see if it is safe and how the body processes it. The drug is being developed to treat high blood pressure. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hangzhou First People's Hospital
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITINGShanghai, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.